Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

We'd appreciate your feedback.Tell us what you think!opens in new tab/window

Elsevier
Publish with us
Video

Clinicalkey AI in action: Risk of gallstones when taking Ozempic?

| 2 min read

ClinicalKey AI combines trusted, evidence-based clinical content with conversational search powered by generative AI to support clinicians in delivering high-quality patient care.  Clinicians gain a powerful ally with ClinicalKey AI by providing quick access to trusted clinical knowledge and allowing them to focus on what truly matters, quality patient care. Interested healthcare organizations can contact us today to learn more.  

ClinicalKey AI Query: What is the risk of gallstones when taking Ozempic?

Ozempic (semaglutide) has been associated with an increased risk of gallstones (cholelithiasis) in clinical studies.[1-2]

  • In clinical trials for type 2 diabetes mellitus (T2DM), cholelithiasis was reported in 1.5% of patients treated with Ozempic 0.5 mg and 0.4% of patients treated with Ozempic 1 mg subcutaneous injection.[1-2]

  • For weight management, the incidence of cholelithiasis was higher in Ozempic-treated pediatric patients 12 years and older compared to adult patients.[1]

  • In clinical trials of Ozempic injection for weight management in adults, cholelithiasis was reported in 1.6% of Ozempic-treated patients compared with 0.7% of placebo-treated patients.[1]

  • Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in Ozempic-treated patients than in placebo-treated patients, even after accounting for the degree of weight loss.[1]

  • Cholecystectomy has been reported during postmarketing use of Ozempic.[1]

References  

  1. Semaglutide.opens in new tab/window  Elsevier ClinicalKey  Drug Monograph. Content last updated: March 20, 2024 

  2. Ozempic. Label via DailyMed.opens in new tab/window  Food and Drug Administration (DailyMed)  FDA 

Answer generated on April 2, 2024 

Note: User acknowledges that these materials are provided for use at no charge as part of Elsevier’s efforts to support healthcare providers and patients. The information contained within the website is intended as a supplement to, and not a substitute for, the knowledge, expertise, skill and judgment of healthcare professionals involved in patient care. The content within this page may not be re-used, modified or re-distributed without prior written permission.